Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer
arcticnovartis
Tue, 12/10/2024 – 15:04
Read more about Longer-term Novartis Kisqali® NATALEE data show…
Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML
arcticnovartis
Sun, 12/08/2024 – 18:34
Read more about Longer-term data for Novartis Scemblix® re…
New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy
arcticnovartis
Fri, 12/06/2024 – 07:19
Read more about New Phase IIIB data shows …
Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence
arcticnovartis
Wed, 11/27/2024 – 07:19
Read more about Novartis Kisqali® receives European Comm…
Novartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS
arcticnovartis
Mon, 11/25/2024 – 07:19
Read more about Novartis highlights new 96-wee…
Novartis upgrades mid-term guidance and highlights deep pipeline in core therapeutic areas to drive long-term growth
arcticnovartis
Thu, 11/21/2024 – 07:04
Read more about Novartis upgrades mid-term guidance and highlights deep pipeline in core th…
Novartis ranks first in 2024 Access to Medicine Index
arcticnovartis
Tue, 11/19/2024 – 14:04
Read more about Novartis ranks first in 2024 Access to Medicine Index
The Index spotlights Novartis leadership in research and development…
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
arcticnovartis
Tue, 10/29/2024 – 20:14
Read more about Novartis Scemblix® FDA approved in newly diagnosed CML, offeri…
Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
arcticnovartis
Tue, 10/29/2024 – 20:14
Read more about Novartis Scemblix® FDA approved in newly diagnosed CML, offeri…
Novartis setzt die starke Dynamik im dritten Quartal fort mit Steigerungen beim Umsatz (+10%) und operativen Kernergebnis (+20%) sowie wichtigen Innovationsmeilensteinen; Prognose für 2024 angehoben
arcticnovartis
Tue, 10/29/2024 – 07:02
Read more…